![]() While the inhibitor of HDLBP has been reported, our work suggested a promising potential of targeting HDLBP to improve the treatment of fatal SCLC and a powerful tool of using cell-SELEX in cancer medicine.Īptamer Cell cycle HDLBP Small cell lung cancer Targeted therapy.Ĭopyright © 2019. Mechanism study revealed the new function of HDLBP in promoting G1/S cell cycle transition for tumor progression. Attenuating HDLBP expression with siRNA inhibited proliferation and metastasis of SCLC cells in vitro and tumor formation in vivo. PMID: 31233742 DOI: 10.1016/j.yexcr.2019.06.023 Abstract Small cell lung cancer (SCLC) has been a recalcitrant cancer without significant breakthroughs in clinical treatment during the past three decades. Immunohistochemistry results showed an elevated HDLBP level in SCLC tissues from clinical samples. Here we identified a new protein biomarker of SCLC, which is high density lipoprotein binding protein (HDLBP), through the aptamer generated by cell-SELEX against SCLC cells. As there is a lack of effective protein inhibitor for SCLC targeted therapy, the discovery of new druggable SCLC biomarkers is a pressing work. Electronic address: cell lung cancer (SCLC) has been a recalcitrant cancer without significant breakthroughs in clinical treatment during the past three decades. ![]()
0 Comments
Leave a Reply. |